SCHEMBL3966091

SCHEMBL3966091

CC(=O)Nc1ccc(S(=O)(=O)NC(C[C@H](C)N)c2cc3c(ccc4cn[nH]c43)o2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 5/20 0.42
GAA P10253 2/20 0.39
ADAMTS4 O75173 2/20 0.39
POLB P06746 3/20 0.38
THRB P10828 1/20 0.38
MAPT P10636 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
MMP13 P45452 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966100 1.00 MMP2 (0.42) MMP2GAAADAMTS4POLBTHRB
SCHEMBL3965562 0.75 HTR2C (0.34) KDM4EALDH1A1HPGD
SCHEMBL3965560 0.75 HTR2C (0.34) KDM4EALDH1A1HPGD
SCHEMBL3966087 0.65 HTR2C (0.57) GAAPOLBTHRBMAPTCA12
SCHEMBL7908701 0.62 POLB (0.68) MMP2ADAMTS4POLBMAPTCA12
SCHEMBL14045319 0.60 ROCK2 (0.77) GAAMAPTROCK2ROCK1KDM4E
SCHEMBL6328987 0.60 POLB (0.60) MMP2ADAMTS4POLBMAPTCA12
SCHEMBL3612325 0.60 MMP2 (1.00) MMP2ADAMTS4MMP13
SCHEMBL13314446 0.60 MMP2 (1.00) MMP2ADAMTS4MMP13
SCHEMBL9603327 0.59 MMP2 (0.64) MMP2GAAADAMTS4POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476687-B2 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2009-01-13 US disclosed
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2009-01-08 US disclosed
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2007-06-14 US disclosed
WO-2005053688-A1 SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma PTGIS, PTGIR, PTGS2 MMP2 2293/4885GAA 1179/4885ADAMTS4 3153/4885
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA PTGIS, PTGIR, PTGS2 MMP2 2293/4885GAA 1179/4885ADAMTS4 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.